London, 8 April 2015. 07:00 AM GMT+1. Norgine B.V. announced today that the United States Patent and Trademark Office (USPTO) granted US Patent No. 8,999,313 covering novel colon cleansing formulations. The inventions were made as part of Norgine’s work to improve the quality and patient acceptability of colon cleansing formulations used before colonoscopy procedures.
Peter Martin, COO said: “This latest patent recognises Norgine’s ongoing commitment to improve colonoscopy as the gold standard procedure for the early detection and prevention of colon cancer. Improving the quality and patient acceptability of colon cleansing has been demonstrated to increase the effectiveness of colonoscopy procedures. This work complements other innovations to improve colonoscopy being brought to the market by Norgine, such as Endocuff Vision, a novel medical device which has been demonstrated to increase the adenoma detection rate during colonoscopy procedures.”
Colorectal cancer is the third leading cause of cancer-related deaths in the United States when men and women are considered separately, and the second leading cause when both sexes are combined. It is expected to cause about 49,700 deaths during 2015.[i]
Notes to Editors:
About Norgine
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine’s total revenue was €296 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Media Contacts
Isabelle Jouin, T: +44 (0)1895 453643
Follow us @norgine
[i] American Cancer Society. What are the key statistics about colorectal cancer?http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics. Accessed 2 April 2015
Job code: GL/MPR/0415/0036